Navigation Links
TriGuard Cerebral Protection Device Shows Reduction in Stroke Rate and Improvement in Patients' Neurological Outcomes in TAVR Procedures
Date:5/18/2016

CAESAREA, Israel and PARIS, May 19, 2016 /PRNewswire/ -- EuroPCR -- Keystone Heart has announced that a pooled analysis of three prospective and comparable clinical studies of patients undergoing TAVR in US and Europe, further corroborates that TriGuard™ protection significantly reduces stroke rate, lowers CNS infarction and reduces total lesion volume, without adversely impacting the safety of the TAVR procedure.

The aim of the analysis was to evaluate the safety and effectiveness of the TriGuard™ HDH embolic deflection device compared to no protection. This was done in a pooled analysis of three prospective and comparable clinical studies of patients undergoing transcatheter valve implantation (TAVR) in the US and Europe. Dr. Alexandra J. Lansky (Division of Cardiology, Yale School of Medicine and Yale Cardiovascular Research Group, New Haven, CT, USA) presented the analysis earlier at EuroPCR, during the late breaking trials session on new valvular interventions and enabling technologies.

TriGuard(TM) Cerebral Protection Device shows reduction in stroke rate and improvement in patients' neurological outcomes in TAVR procedures. TriGuard(TM) is designed to provide full coverage to all brain territories during TAVR and other cardiovascular procedures.
TriGuard(TM) Cerebral Protection Device shows reduction in stroke rate and improvement in patients' neurological outcomes in TAVR procedures. TriGuard(TM) is designed to provide full coverage to all brain territories during TAVR and other cardiovascular procedures.

The patient level data was pooled from a total of 142 patients undergoing TAVR with TriGuard™ protection (N=59) vs. no protection (N=83). The data was pooled from three trials (DEFLECT I, DEFLECT III and Neuro TAVR) evaluating neurologic complications with and without cerebral protection during TAVR. All three trials mandated pre-discharge diffusion weighted MRI (DW-MRI) and performed serial neurologic assessments using the same methods and core laboratories.

Key results were as follows:

  • TriGuard protection significantly reduced in hospital VARC2 defined stroke (0% vs. 6.0%, p=0.05)
  • TriGuard protection significantly reduced stroke rate defined by worsening NIHSS (National Institutes of Health Stroke Scale) with DW-MRI lesions (0% vs. 19%, p=0.002)
  • TriGuard protected patients showed higher absence of CNS infarction (28% vs. 8%, p=0.008)
  • Total lesion volume was reduced significantly with TriGuard vs. no protection (315+620mm3 vs. 511+893mm3, p=0.04)
  • None of the TriGuard protected patients had worsened NIHS score, while 17.1% of the patients without protection had worsened NIHS score (p=0.001)

These clinically meaningful outcomes, clearly demonstrate the importance of using TriGuard, and the potential consequences of unprotected procedures. 

Keystone Heart's TriGuard™ is the only cerebral protection device specifically designed to provide full coverage to all aortic arch takeoffs. The CE marked TriGuard™ Cerebral Protection Device is not yet commercially available in the USA.

About Keystone Heart
Keystone Heart Ltd. is a medical device company developing and manufacturing cerebral protection devices to reduce the risk of stroke, neurocognitive decline and dementia caused by brain emboli associated with cardiovascular procedures.

The Company is focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR, surgical valve replacement, atrial fibrillation ablation and other cardiovascular procedures. The TriGuard product pipeline is designed to help interventional cardiologists, electrophysiologists and cardiac surgeons to preserve brain reserve while performing these procedures.

Headquartered in Israel, Keystone Heart is dedicated to advancing patient care through innovative technology and clinical research. The Company's management has extensive experience in the fields of interventional cardiology and medical devices.

Contact:
Mr. Shuki Porath, President and CEO  
info@keystoneheart.com 
Tel:  +972 4 615 8000
www.keystoneheart.com

Photo - http://photos.prnewswire.com/prnh/20160518/369170  
Logo - http://photos.prnewswire.com/prnh/20160518/369169LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/triguard-cerebral-protection-device-shows-reduction-in-stroke-rate-and-improvement-in-patients-neurological-outcomes-in-tavr-procedures-300271156.html


'/>"/>
SOURCE Keystone Heart
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. New Clinical Data Presented at EuroPCR Demonstrates that TriGuard Reduces Brain Lesion Volume during TAVR
2. Flowonix Medical Inc. and Cerebral Therapeutics, LLC Announce Exclusive Agreement for Drug Delivery to Brain
3. Il Collegio Internazionale di Neuropsicofarmacologia (CINP) chiede ai governi di arginare la preoccupante indisponibilità di nuovi farmaci da destinare al 10% della popolazione mondiale affetta da patologie cerebrali
4. MicroVention Announces First Trial Enrollment In Their U.S. Clinical Trial Of Its New Dual-Layer Stent For Cerebral Aneurysm Flow Diversion
5. Passavant Area Hospital Bolsters Already Stringent Cleaning Protocols for Added Patient Protection
6. Statement from the Patients Alliance for Drug Safety Protections on the Need for Restricted Distribution Systems for High-Risk Medicines
7. Global Market Study on Hearing Protection Devices: Stringent Safety Regulations and Increasing Demand for Reusable Earplugs to Drive the Market, Persistence Market Research
8. Pharmacy - Pill Dust - Patient Protection: Madigan Patient Safety - Product Innovation Foundation Announces New Patented Product That Eliminates Dangers Related to Compromised Prescription Medication
9. Global Neuroprotection Market Report 2015 - 500 Products Have Been Investigated for Neuroprotective Effects
10. Studies Show Respiratory Volume Monitoring May Offer Better Protection for Women in Labor and Obese Patients
11. Online Catalog Update - Includes Over 50 Top OEMs and Over 600 Models for Power Protection of Laboratory Instruments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... May 17, 2017  Bayer announced today that the ... be presented at the 53 rd Annual Meeting ... place June 2-6 in Chicago . ... span prostate, colorectal, liver and thyroid cancers, as well ... Phase II CHRONOS-1 trial of copanlisib in patients with ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
(Date:5/11/2017)...  Thornhill Research Inc. ( Toronto, Ontario, ... USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by the U.S. ... (CCC) ( Ottawa, Ontario, Canada ) ... anesthesia to patients requiring emergency medical procedures in ... Corps have been a longtime partner with Thornhill ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... the Peace Agreements being discussed by President Donald Trump and the rest of the ... to speed up peace talks in the continuous battle between Israel and Palestine. The ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... “When the ... Lead Home” is the creation of published author Laura Weigel Douglas, an avid reader ... cat in a house that sometimes feels like Green Hills Adventure Camp. She couldn’t ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Cactus Jack: Against All Odds”: ... many others. “Cactus Jack: Against All Odds” is the creation of published author, ... Hubbard is married to Jack Carlisle’s third child Jane. Walter. Walter and Jane ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Dr. Alan ... surgery in New York City. He is known for his distinguished expertise and ... vascular surgery, Dr. Benvenisty holds sub-specialty training in treating renovascular disease and aortic ...
(Date:5/24/2017)... ... ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is now welcoming new ... Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can take on patients’ ... longer need to feel the esthetic effects of wires and brackets when they can ...
Breaking Medicine News(10 mins):